BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 25903574)

  • 1. Comparison of Onclarity Human Papillomavirus (HPV) Assay with Hybrid Capture II HPV DNA Assay for Detection of Cervical Intraepithelial Neoplasia Grade 2 and 3 Lesions.
    Bottari F; Sideri M; Gulmini C; Igidbashian S; Tricca A; Casadio C; Carinelli S; Boveri S; Ejegod D; Bonde J; Sandri MT
    J Clin Microbiol; 2015 Jul; 53(7):2109-14. PubMed ID: 25903574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and Analytical Performance of the BD Onclarity HPV Assay with SurePath Screening Samples from the Danish Cervical Screening Program Using the VALGENT Framework.
    Bonde JH; Pedersen H; Quint W; Xu L; Arbyn M; Ejegod DM
    J Clin Microbiol; 2020 Jan; 58(2):. PubMed ID: 31723012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison Study of BD Onclarity HPV With digene HC2 High-Risk HPV DNA Test and Roche Cobas 4800 HPV for Detecting High-Risk Human Papillomavirus in Japan.
    Nakamura M; Nakade K; Orisaka S; Iwadare J; Mizumoto Y; Fujiwara H
    Am J Clin Pathol; 2019 Feb; 151(3):263-269. PubMed ID: 30260388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical performance of the BD Onclarity HPV assay using an adjudicated cohort of BD SurePath liquid-based cytology specimens.
    Wright TC; Stoler MH; Agreda PM; Beitman GH; Gutierrez EC; Harris JM; Koch KR; Kuebler M; LaViers WD; Legendre BL; Leitch SV; Maus CE; McMillian RA; Nussbaumer WA; Palmer ML; Porter MJ; Richart GA; Schwab RJ; Vaughan LM
    Am J Clin Pathol; 2014 Jul; 142(1):43-50. PubMed ID: 24926084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions.
    Arbyn M; Roelens J; Simoens C; Buntinx F; Paraskevaidis E; Martin-Hirsch PP; Prendiville WJ
    Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD008054. PubMed ID: 23543559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Aptima and hybrid capture-2 HPV tests and Pap test in the referral population in Japan.
    Kuroki H; Sakamoto J; Shibata T; Takakura M; Sasagawa T
    J Med Virol; 2021 Aug; 93(8):5076-5083. PubMed ID: 33634473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and Analytical Performance of the Onclarity HPV Assay Using the VALGENT Framework.
    Cuschieri K; Geraets DT; Moore C; Quint W; Duvall E; Arbyn M
    J Clin Microbiol; 2015 Oct; 53(10):3272-9. PubMed ID: 26246482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agreement between the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease.
    Carozzi F; Bisanzi S; Sani C; Zappa M; Cecchini S; Ciatto S; Confortini M
    J Clin Microbiol; 2007 Feb; 45(2):364-9. PubMed ID: 17122008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of the NucliSENS EasyQ HPV assay in the management of cervical intraepithelial neoplasia.
    Oliveira A; Verdasca N; Pista Â
    J Med Virol; 2013 Jul; 85(7):1235-41. PubMed ID: 23918542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytology versus HPV testing for cervical cancer screening in the general population.
    Koliopoulos G; Nyaga VN; Santesso N; Bryant A; Martin-Hirsch PP; Mustafa RA; Schünemann H; Paraskevaidis E; Arbyn M
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD008587. PubMed ID: 28796882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in Germany.
    Iftner T; Becker S; Neis KJ; Castanon A; Iftner A; Holz B; Staebler A; Henes M; Rall K; Haedicke J; von Weyhern CH; Clad A; Brucker S; Sasieni P
    J Clin Microbiol; 2015 Aug; 53(8):2509-16. PubMed ID: 26019212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection and genotyping of HPV-DNA through different types of diagnostic platforms in liquid-based cervical-cytology samples.
    Cassani B; Soldano G; Finocchiaro D; Conti S; Bulfamante A; Lemorini G; Bulfamante G
    Pathologica; 2018 Dec; 110(4):294-301. PubMed ID: 30799441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and analytical performance of the BD Onclarity™ HPV assay for detection of CIN2+ lesions on SurePath samples.
    Ejegod DM; Junge J; Franzmann M; Kirschner B; Bottari F; Sideri M; Sandri MT; Bonde J
    Papillomavirus Res; 2016 Dec; 2():31-37. PubMed ID: 29074183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Machine Learning Interpretation of Extended Human Papillomavirus Genotyping by Onclarity in an Asian Cervical Cancer Screening Population.
    Wong OGW; Ng IFY; Tsun OKL; Pang HH; Ip PPC; Cheung ANY
    J Clin Microbiol; 2019 Dec; 57(12):. PubMed ID: 31511337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Head-to-Head Comparison of DH3 HPV Test and HC2 Assay for Detection of High-Risk HPV Infection in Residual Cytology Samples from Cervical Cancer Screening Setting: Baseline and 3-Year Longitudinal Data.
    Fu Y; Li X; Li Y; Lu W; Xie X; Wang X
    Microbiol Spectr; 2022 Feb; 10(1):e0157021. PubMed ID: 35171029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of Cervical Neoplasia by Human Papillomavirus Testing in an Atypical Squamous Cells-Undetermined Significance Population: Results of the Becton Dickinson Onclarity Trial.
    Wright TC; Stoler MH; Parvu V; Yanson K; Eckert K; Kodsi S; Cooper CK
    Am J Clin Pathol; 2019 Jan; 151(1):53-62. PubMed ID: 30189049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective comparison of hybrid capture 2 and SPF₁₀-LiPA for carcinogenic human papillomavirus detection and risk prediction of cervical cancer: a population-based cohort study in China.
    Dong L; Feng RM; Zhang L; Xu XQ; Zhao XL; Wang MZ; Qiao YL; Zhao FH
    J Gynecol Oncol; 2017 Sep; 28(5):e66. PubMed ID: 28657227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HPV Testing With 16, 18, and 45 Genotyping Stratifies Cancer Risk for Women With Normal Cytology.
    Stoler MH; Wright TC; Parvu V; Yanson K; Eckert K; Kodsi S; Cooper C
    Am J Clin Pathol; 2019 Mar; 151(4):433-442. PubMed ID: 30649177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Onclarity Human Papillomavirus Extended Genotyping in the Management of Cervical Intraepithelial Neoplasia 2+ Lesions.
    Bottari F; Iacobone AD; Boveri S; Preti EP; Franchi D; Mariani L; Preti M; Landoni F; Passerini R; Sandri MT
    J Low Genit Tract Dis; 2019 Jan; 23(1):39-42. PubMed ID: 30371554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical performance of Abbott RealTime High Risk HPV test for detection of high-grade cervical intraepithelial neoplasia in women with abnormal cytology.
    Huang S; Erickson B; Tang N; Mak WB; Salituro J; Robinson J; Abravaya K
    J Clin Virol; 2009 Jul; 45 Suppl 1():S19-23. PubMed ID: 19651364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.